Cytosorbents Corp Dossier
Qualitative Analysis
Business overview
CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and cardiac surgery through blood purification. The company's proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. In the United States and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device designed to reduce the severity of perioperative bleeding in high-risk cardiac surgery due to blood-thinning drugs.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive restructuring program implemented in Q4 2025 that included a 10% reduction in workforce, along with the realignment of production and operating expenses to optimize operations.
Expected impact: Accelerate the timeline to achieve operating cash flow break-even in the second half of 2026.
A significant restructuring of the direct sales team and commercial strategy in Germany (the company's largest market for the CytoSorb device), involving the rebalancing of territories and hospital accounts.
Expected impact: Restore sales growth in Germany through deeper customer engagement, more effective market development, and improved sales representative productivity.
Advancing the regulatory strategy for DrugSorb-ATR in the U.S. by preparing a new De Novo application for Brilinta removal and a separate pre-submission for DOAC removal.
Expected impact: Establish a commercial foothold in the U.S. and Canadian markets for antithrombotic drug removal during urgent cardiothoracic surgeries.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Renewal of the partnership to distribute and develop blood purification therapies, strengthening CytoSorbents' commercial footprint in key European markets.
Terms: Not explicitly disclosed.